Related to FDA Details Requirements for Regulatory Submissions of Genomic Biomarkers

• Autologous Immunotherapy Updates at ASCO Further Define Antitumor Immune Responses
  Biovest and Dendreon presented studies involving their respective vaccines in the neoadjuvant setting.
  
• Why Biomarker Discovery Is Hard
  Differentiating which markers are in the driver’s seat and which are along for the ride is key.
  
• Blood Flow as Diagnostic Marker
  Jamming, or vaso-occlusion, could be used to distinguish sickle cell disease patients with poor outcomes from those with good outcomes.
  
• The Search for Depression Biomarkers
  The ability to predict drug responses more accurately is driving efforts.
  
• Cliff Spells Danger for Biotechs
  If Obama and Congress cannot agree, key agencies face cuts while tax changes would dampen new investment.
  
• Building a Self-Destructive Mosquito
  Genetically modified mosquitos could be a way to curb the spread of dengue fever in Florida.
  
• Literature Review: ELISA—Detected Through A Quick Glance
  Researchers provide an assay chemistry that allows for a direct visual scoring of an ELISA result to detect protein analytes at ultralow concentrations.
  
• DNA Methylation Rules: Studying Epigenetics with New Tools
  The tools to unravel the epigenetic control mechanisms that influence how cells control access of transcriptional proteins to DNA are just beginning to emerge.
  
• Biosimilars: Not So Far So Fast
  Regulatory issues are among the hurdles that are slowing down biosimilar production.
  
• Osiris’ Race to Market an FDA-Approved Stem Cell Product
  Mesenchymal stem cell therapy Prochymal is in Phase III but still has challenges to overcome.
  
• Changes Brewing at the FDA for Orphan Drugs
  Initiatives to de-risk drug development could include redesigning clinical trial requirements.
  
• FDA Panel Hearing Suggests Medical Professionals May Play Role in Direct-to-Consumer Testing
  Changes including more regulation may take some time, as recommendations for the agency are yet to be finalized.
  
• NIH and FDA Taking Partnership for Regulatory and Translational Science One Step at a Time
  Over the past year, initiative named members, held two meetings, and gave out $9.4 million.
  
• FDA Outlines Strategic Priorities but Action Is Further Out
  The agency will take at least another year to flesh out plans.
  
• FDA Tries to Address Some Concerns Over Nanotech in Biotech
  More details are needed, but developers now have a better idea of what constitutes nanomaterials.
  
• Genentech Prepares to Vouch for Avastin’s Use in Breast Cancer in FDA Hearing
  Company will present details on a so-called confirmatory study and biomarker data.
  
• Diagnostic Market Stakeholders Take Aim at FDA’s RUO/IUO Draft Guidance
  Among potential changes is that manufacturers will have to anticipate customers’ intended use of their IVD products.
  
• Concurrent Dx/Rx Review Will Require More Collaboration at FDA and More Outreach by Industry
  Agency issued draft guidance on companion diagnostic approval on July 14.
  
• As Comment Period Ends, FDA Seeks to Clarify Conflict of Interest Rules
  Agency’s draft guidance should be coupled with HHS’ proposals from last year, which are still being reviewed.
  
• Efforts to Standardize Molecular Imaging Blossoms as Industry and Agencies Unite
  Firms are more interested in leveraging the value of this method in clinical development.